• Contact

  • Newsletter

  • About us

  • Delivery options

  • Prospero Book Market Podcast

  • Quantitative Decisions in Drug Development

    Quantitative Decisions in Drug Development by Chuang-Stein, Christy; Kirby, Simon;

    Series: Springer Series in Pharmaceutical Statistics;

      • GET 12% OFF

      • The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
      • Publisher's listprice EUR 108.99
      • The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.

        45 203 Ft (43 051 Ft + 5% VAT)
      • Discount 12% (cc. 5 424 Ft off)
      • Discounted price 39 779 Ft (37 885 Ft + 5% VAT)

    45 203 Ft

    Availability

    Uncertain availability. Please turn to our customer service.

    Why don't you give exact delivery time?

    Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.

    Product details:

    • Edition number 1st ed. 2017
    • Publisher Springer, Berlin
    • Date of Publication 1 January 2017
    • Number of Volumes 1 pieces, Book

    • ISBN 9783319460758
    • Binding Hardback
    • No. of pages248 pages
    • Size 239x162x21 mm
    • Weight 552 g
    • Language English
    • Illustrations 16 SW-Abb., 11 Farbabb. Illustrations, black & white
    • 0

    Categories

    Short description:

    This book offers a high-level treatise of evidence-based decisions in drug development. Because of the inseparable relationship between designs and decisions, a good portion of this book is devoted to the design of clinical trials. The book begins with an overview of product development and regulatory approval pathways. It then discusses how to incorporate prior knowledge into study design and decision making at different stages of drug development. The latter include selecting appropriate metrics to formulate decisions criteria, determining go/no-go decisions for progressing a drug candidate to the next stage and predicting the effectiveness of a product. Lastly, it points out common mistakes made by drug developers under the current drug-development paradigm.

    The book offers useful insights to statisticians, clinicians, regulatory affairs managers and decision-makers in the pharmaceutical industry who have a basic understanding of the drug-development process and the clinical trials conducted to support drug-marketing authorization.

    The authors provide software codes for select analytical approaches discussed in the book. The book includes enough technical details to allow statisticians to replicate the quantitative illustrations so that they can generate information to facilitate decision-making themselves.

    More

    Long description:

    This book offers a high-level treatise of evidence-based decisions in drug development. Because of the inseparable relationship between designs and decisions, a good portion of this book is devoted to the design of clinical trials. The book begins with an overview of product development and regulatory approval pathways. It then discusses how to incorporate prior knowledge into study design and decision making at different stages of drug development. The latter include selecting appropriate metrics to formulate decisions criteria, determining go/no-go decisions for progressing a drug candidate to the next stage and predicting the effectiveness of a product. Lastly, it points out common mistakes made by drug developers under the current drug-development paradigm.

    The book offers useful insights to statisticians, clinicians, regulatory affairs managers and decision-makers in the pharmaceutical industry who have a basic understanding of the drug-development process and the clinical trials conducted to support drug-marketing authorization.

    The authors provide software codes for select analytical approaches discussed in the book. The book includes enough technical details to allow statisticians to replicate the quantitative illustrations so that they can generate information to facilitate decision-making themselves.



    "This work offers useful algorithms, classifications, and other general points to statisticians or 'quantitative scientists'. But, it is also really useful to regulatory affairs managers, clinicians, medical writers, and all kinds of decision-makers in the industry." (Andrei Myslivets, ISCB News, Vol. 68, December, 2019)
    "It is presented in a concise, structured, friendly, and illustrative way that allows for a good understanding of the underlying ideas ... . the book from Chuang-Stein and Kirby is a valuable, interesting and easy read for statisticians and clinicians with some methodological background who are involved in clinical development or drug approval and who are looking for a structured way to make clinical development decisions." (Norbert Benda, Biometrical Journal, Vol. 61 (4), July, 2016)

    More